Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

Robert B. Zipursky, Hongbin Gu, Alan I. Green, Diana O. Perkins, Mauricio F. Tohen, Joseph Patrick McEvoy, Stephen M. Strakowski, Tonmoy Sharma, René S. Kahn, Raquel E. Gur, Gary D. Tollefson, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Background: Substantial weight gain is common with many atypical antipsychotics. Aims: To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol. Method: Survival analysis assessed time to potentially clinically significant weight gain (≥ 7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches. Results: After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001). Conclusions: Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

Original languageEnglish (US)
Pages (from-to)535-543
Number of pages9
JournalBritish Journal of Psychiatry
Volume187
Issue numberDEC.
StatePublished - Dec 1 2005

Fingerprint

olanzapine
Haloperidol
Psychotic Disorders
Weight Gain
Observation
Survival Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., ... Lieberman, J. A. (2005). Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. British Journal of Psychiatry, 187(DEC.), 535-543.

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. / Zipursky, Robert B.; Gu, Hongbin; Green, Alan I.; Perkins, Diana O.; Tohen, Mauricio F.; McEvoy, Joseph Patrick; Strakowski, Stephen M.; Sharma, Tonmoy; Kahn, René S.; Gur, Raquel E.; Tollefson, Gary D.; Lieberman, Jeffrey A.

In: British Journal of Psychiatry, Vol. 187, No. DEC., 01.12.2005, p. 535-543.

Research output: Contribution to journalArticle

Zipursky, RB, Gu, H, Green, AI, Perkins, DO, Tohen, MF, McEvoy, JP, Strakowski, SM, Sharma, T, Kahn, RS, Gur, RE, Tollefson, GD & Lieberman, JA 2005, 'Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol', British Journal of Psychiatry, vol. 187, no. DEC., pp. 535-543.
Zipursky, Robert B. ; Gu, Hongbin ; Green, Alan I. ; Perkins, Diana O. ; Tohen, Mauricio F. ; McEvoy, Joseph Patrick ; Strakowski, Stephen M. ; Sharma, Tonmoy ; Kahn, René S. ; Gur, Raquel E. ; Tollefson, Gary D. ; Lieberman, Jeffrey A. / Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. In: British Journal of Psychiatry. 2005 ; Vol. 187, No. DEC. pp. 535-543.
@article{a2608b82a0df48cc90d578507ef85f01,
title = "Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol",
abstract = "Background: Substantial weight gain is common with many atypical antipsychotics. Aims: To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol. Method: Survival analysis assessed time to potentially clinically significant weight gain (≥ 7{\%}) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches. Results: After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001). Conclusions: Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.",
author = "Zipursky, {Robert B.} and Hongbin Gu and Green, {Alan I.} and Perkins, {Diana O.} and Tohen, {Mauricio F.} and McEvoy, {Joseph Patrick} and Strakowski, {Stephen M.} and Tonmoy Sharma and Kahn, {Ren{\'e} S.} and Gur, {Raquel E.} and Tollefson, {Gary D.} and Lieberman, {Jeffrey A.}",
year = "2005",
month = "12",
day = "1",
language = "English (US)",
volume = "187",
pages = "535--543",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "DEC.",

}

TY - JOUR

T1 - Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

AU - Zipursky, Robert B.

AU - Gu, Hongbin

AU - Green, Alan I.

AU - Perkins, Diana O.

AU - Tohen, Mauricio F.

AU - McEvoy, Joseph Patrick

AU - Strakowski, Stephen M.

AU - Sharma, Tonmoy

AU - Kahn, René S.

AU - Gur, Raquel E.

AU - Tollefson, Gary D.

AU - Lieberman, Jeffrey A.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Background: Substantial weight gain is common with many atypical antipsychotics. Aims: To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol. Method: Survival analysis assessed time to potentially clinically significant weight gain (≥ 7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches. Results: After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001). Conclusions: Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

AB - Background: Substantial weight gain is common with many atypical antipsychotics. Aims: To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol. Method: Survival analysis assessed time to potentially clinically significant weight gain (≥ 7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches. Results: After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001). Conclusions: Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.

UR - http://www.scopus.com/inward/record.url?scp=28644433423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28644433423&partnerID=8YFLogxK

M3 - Article

C2 - 16319406

AN - SCOPUS:28644433423

VL - 187

SP - 535

EP - 543

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - DEC.

ER -